Could Tecentriq's Bladder Cancer Setback Be A Class Effect?
The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?
You may also be interested in...
In patients with previously untreated metastatic bladder cancer with low PD-L1 expression, PD-1 drugs alone don't work as well as chemo.
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.